Full text
Earnings transcript
Read the complete earnings call transcript.
PEN
Penumbra, Inc.
$322.38
-0.67
(-0.21%)
| Exchange: | NYSE |
| Market Cap: | 12.698B |
| Shares Outstanding: | 24.511M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Adam Elsesser | |||||
| Full Time Employees: | 4700 | |||||
| Address: |
| |||||
| Website: | https://www.penumbrainc.com |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,058,522 | 1,194,615 | 1,403,665 |
| Gross Profit | 682,643 | 754,995 | 942,437 |
| EBITDA | 108,646 | 45,989 | 223,907 |
| Operating Income | 73,551 | 86,224 | 189,249 |
| Net Income | 90,954 | 14,012 | 177,687 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,556,305 | 1,533,181 | 1,826,519 |
| Total Liabilities | 377,361 | 382,250 | 398,916 |
| Total Stockholders Equity | 1,178,944 | 1,150,931 | 1,427,603 |
| Total Debt | 234,343 | 223,389 | 219,699 |
| Cash and Cash Equivalents | 167,486 | 324,404 | 186,897 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 97,333 | 168,481 | 238,663 |
| Capital Expenditure | -15,213 | -21,182 | -63,729 |
| Free Cash Flow | 82,120 | 147,299 | 174,934 |
| Net Income | 90,954 | 14,012 | 177,687 |
| Net Change in Cash | 97,628 | 156,918 | -137,507 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 2,123,089.854 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 2,178,407.684 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 2,154,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 147,132.948 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 150,966.547 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 149,275.063 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 307,699.420 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 318,167.549 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 313,548.795 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 1,048,172.459 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 1,075,482.950 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 1,063,432.842 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 7.980 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 8.100 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 7.830 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 6 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Growth: Penumbra reported strong revenue of $339.5 million in Q2 2025, reflecting consistent growth as highlighted in the earnings call transcript. This performance aligns with positive industry trends in the medical devices sector, showcasing the company’s ability to capitalize on market demand.
- Innovative Product Portfolio: The earnings call emphasized strategic investments in product development, contributing to sustained growth in key segments. This focus on innovation positions Penumbra as a leader within its industry, as evidenced by strong gross profit margins (specific figures to be derived from Key Metrics data).
- Solid Financial Position: High operating cash flow and free cash flow (as per Cash Flow Statements data) indicate operational efficiency and the ability to fund further investments without excessive reliance on external financing, providing a strong financial foundation.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates PEN intrinsic value between $55.20 – $650.28 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about PEN valuation
Is Penumbra, Inc. (PEN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Penumbra, Inc. (PEN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is PEN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PEN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is PEN’s P/E ratio?
You can see PEN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for PEN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is PEN a good long-term investment?
Whether PEN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
PEN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.21
Trading Metrics:
| Open: | 323 | Previous Close: | 323.05 | |
| Day Low: | 322.01 | Day High: | 323.09 | |
| Year Low: | 221.26 | Year High: | 362.41 | |
| Price Avg 50: | 320.45 | Price Avg 200: | 322.92 | |
| Volume: | 149712 | Average Volume: | 404575 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freePEN full analysis
Welcome to MARKETSNAP’s SWOT analysis for Penumbra, a name that might not be on everyone’s radar but definitely deserves a closer look if you’re hunting for growth in the healthcare space. Today, we’re diving deep into what makes this company tick, breaking down its strengths, weaknesses, opportunities, and threats, all while keeping an eye on how it fits into a long-term investment strategy. So, grab a coffee, let’s chat about Penumbra, and see if it’s a potential gem for your…
